Published: February 26, 2013 at 1:16 pm

Google Inc. (NASDAQ:GOOG) – third most-popular holding among equity hedge funds that we track – just might have to pay rent in European Union courtrooms, as the company’s attorneys have been taking up residence with all of the legal cases that the tech giant has been dealing with in several Eu countries. The latest battle has moved beyond a regional court and has gone into the full EU judicial system. And what is the issue? Drum roll please …

User privacy. I know, surprising, huh?

The question before the European Court of Justice (ECJ) is determining the point when information should be private when it comes to the internet. Google Inc. (NASDAQ:GOOG) was across the table from the Spain data protection authority giving preliminary arguments involving a case surrounding a private Spanish citizen. An ECJ advocate is due to give an opinion in June, with the judges making a final verdict by the end of the year.

The case involves a person who failed to make social security payments, lost a house in an auction in order to make the payments, and that information was available to view through a Google search. The question is, does that person have the right to force Google Inc. (NASDAQ:GOOG) to scrub embarrassing information from its search results? Legal analysts see this case surrounding several issues – the freedom to information, data-protection rights, defining a publisher and who is the final arbiter of the internet.

Google Inc. (NASDAQ:GOOG) is arguing that it should not be forced to remove content that is legal and it did not create originally. However, Spanish officials made the argument that when an individual’s privacy is compromised, Google should in good faith remove that information from its results.

What is the genesis of this case, and how might Google’s role be defined?

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.